Evidence map›Paper›PMID 31661561›Full record

ArticleBiometrical journal. Biometrische Zeitschrift2020

Extensions of the probabilistic ranking metrics of competing treatments in network meta-analysis to reflect clinically important relative differences on many outcomes.

Dimitris Mavridis, Raphaël Porcher, Adriani Nikolakopoulou, Georgia Salanti, Philippe Ravaud

Open access · hybridAbstract read
In one paragraph

Article in Biometrical journal. Biometrische Zeitschrift, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Network Meta-Analysis Techniques for Synthesizing Prevention Science Evidence.Prevention science : the official journal of the Society for Prevention Research · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 4 countries.

Dimitris MavridisDepartment of Primary Education, University of Ioannina, Ioannina, Greece.ORCID 0000-0003-1041-4592
Raphaël PorcherFaculté de Médecine, Université Paris Descartes, Paris, France.
Adriani NikolakopoulouInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Georgia SalantiInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Philippe RavaudFaculté de Médecine, Université Paris Descartes, Paris, France.
Délégation Paris 5 · FRUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the key features of network meta-analysis is ranking of interventions according to outcomes of interest. Ranking metrics are prone to misinterpretation because of two limitations associated with the current ranking methods. First, differences in relative treatment effects might not be clinically important and this is not reflected in the ranking metrics. Second, there are no established methods to include several health outcomes in the ranking assessments. To address these two issues, we extended the P-score method to allow for multiple outcomes and modified it to measure the mean extent of certainty that a treatment is better than the competing treatments by a certain amount, for example, the minimum clinical important difference. We suggest to present the tradeoff between beneficial and harmful outcomes allowing stakeholders to consider how much adverse effect they are willing to tolerate for specific gains in efficacy. We used a published network of 212 trials comparing 15 antipsychotics and placebo using a random effects network meta-analysis model, focusing on three outcomes; reduction in symptoms of schizophrenia in a standardized scale, all-cause discontinuation, and weight gain.

Indexed as

Meta-Analysis as TopicBiometryTreatment Outcomebenefit-risk assessmentclinically important valuemultiple outcomesnetwork meta-analysisranking metrics

Identifiers

PMID31661561
PMCPMC7078966
OpenAlexW2982528815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.